BFM
ACRS icon

Boothbay Fund Management’s Aclaris Therapeutics ACRS Stock Holding History

Boothbay Fund Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-123,500
Closed -$846K – 1617
2023
Q3 		$846K Sell
123,500
-39,600
-24% -$338K 0.02% 833
2023
Q2 		$1.69M Buy
163,100
+12,500
+8% +$113K 0.04% 622
2023
Q1 		$1.22M Buy
+150,600
New +$1.91M 0.03% 911
2018
Q3 		– Sell
-158
Closed -$316K – 770
2018
Q2 		$316K Buy
+158
New +$2.92K 0.03% 460

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Boothbay Fund Management's ACRS Position: Q2 2025 in Review

Boothbay Fund Management sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 53,478 shares — an estimated $81.8K sold.

Boothbay Fund Management first reported a position in ACRS in Q4 2016 and held it in 12 quarters. The position peaked at $535K in Q3 2017. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • Boothbay Fund Management reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 53,478 Aclaris Therapeutics shares in Q2 2025, an estimated $81.8K.
  • Boothbay Fund Management first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 12 quarters.
  • Boothbay Fund Management's Aclaris Therapeutics position peaked at $535K in Q3 2017.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.